Braidwell’s Aardvark Therapeutics AARD Stock Holding History

Braidwell’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-500,000	Closed	-$3.75M	–	68
2025 Q1	$3.75M	Buy	+500,000	New	+$5.61M	0.13%	59

Other funds holding AARD

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Braidwell's AARD Position: Q2 2025 in Review

Braidwell sold out of Aardvark Therapeutics (AARD) in Q2 2025, closing a stake of 500,000 shares — an estimated $3.75M sold.

Braidwell first reported a position in AARD in Q1 2025 and held it in 1 quarter. The position peaked at $3.75M in Q1 2025. 35 funds tracked by Wall St. Rank hold AARD as of Q2 2025.

Braidwell reported no remaining Aardvark Therapeutics position as of Q2 2025 after selling out during the quarter.
Braidwell sold 500,000 Aardvark Therapeutics shares in Q2 2025, an estimated $3.75M.
Braidwell first reported a position in Aardvark Therapeutics in Q1 2025 and held it in 1 quarter.
Braidwell's Aardvark Therapeutics position peaked at $3.75M in Q1 2025.
35 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2025.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.